Drug Sponsors

Enter Romania And Bulgaria

Thursday, January 4, 2007

The European Union (EU) will have two new member states next month: Romania and Bulgaria. Both countries are ready to implement the EU Clinical Trials Directive, but their membership may have broader implications for clinical research than just harmonized regulations.

[Read More]

Don’t Be Outfoxed By Dems’ Win

Tuesday, November 14, 2006

The Democrats’ decisive victory in Tuesday’s mid-term election put them in control of the House, but it is widely seen as bad news for the pharmaceutical industry. Dire predictions of drug price controls have many in big pharma concerned. Pharma should be worried—especially if it sticks to the old game plan.

[Read More]

Phase Forward reports 26% increase in third quarter revenue

Monday, October 30, 2006

Waltham, Mass.-based Phase Forward reported a 26% increase in third quarter 2006 revenues compared with the same period in 2005. The company reported third quarter revenues of $28 million, up from $22.2 million last year. For the fourth quarter of 2006, the company reported it expects revenues to be between $29.2 and $30.0 million. Income from operations was $4 million, showing a margin of 14.2% and an increase of 66% from the prior year period. The company reported expected revenues for the entire 2006 fiscal year to be between $105.6 and $106.4 million. On non-GAAP basis, the company expects EPS between $0.37 and $0.38.

[Read More]

Painless Growth?

Monday, October 9, 2006

Big Pharma continues to expand into the vaccine market as Pfizer purchased privately owned PowderMed this week, hoping for an ouch-free entry into this segment. The vaccine market is suddenly looking golden to Big Pharma when just a few years ago it seemed that most drugmakers wouldn’t go near vaccines.

[Read More]

Cultivate Your Clinical Researchers, Pharma

Friday, August 25, 2006

Pharma companies know they have to reach out to new and inexperienced investigators to maintain capacity for growth in emerging regions. Investigator capacity is a major issue in these markets because they have experienced such significant growth in recent years. In the U.S., though, companies have taken more of a sink-or-swim approach when introducing physicians to clinical research, and they could be making a big mistake.

[Read More]

Trial Registries Proliferate: Is Anyone Benefiting?

Wednesday, August 2, 2006

The issue of clinical trial result transparency continues to evolve at a rapid pace. During the past few years, almost every stakeholder has taken action in some form.  This should be a positive development because there is a lot attention being focused on a very important issue. But at the end of the day, have we made a difference? Has the noise that this caused just confused the issue more for patients and physicians, or made finding trial information easier and more useful?

[Read More]